MORNING VS EVENING DOSING WITH DOXAZOSIN IN BENIGN PROSTATIC HYPERPLASIA - EFFICACY AND SAFETY

Three hundred and fifty-three patients with symptomatic benign prostat ic hyperplasia were randomized to doxazosin or placebo, with morning o r evening dosing, to compare the effect of dosing time on the efficacy and safety of doxazosin treatment. After 24 weeks of treatment, the m ean International Prostate Symptom Score had decreased by 6.8 units in the doxazosin group compared with 4.5 units in the placebo group (P = 0.003). Improvements in Q(max) of 2.03 ml/s and 0.30 ml/s were seen f or the doxazosin and the placebo groups, respectively (P < 0.001). No differences in efficacy or safety between the morning- and evening-dos ed subgroups were observed. Doxazosin was significantly more effective than placebo at improving symptoms of BPH and urinary flow rates at e ndpoint, and was well tolerated. The time of dosing did not appear to influence the efficacy or safety of doxazosin, suggesting that there i s no need to restrict administration of doxazosin to the evening in BP H patients.